Keep a close eye on Ariad Pharmaceuticals (ARIA). Check this out:
Shares of Ariad Pharmaceuticals Inc.(ARIA) soared $1.35 (or +35.74%) to $5.13 on Monday's market activity.
Last week, ARIA reported adoption of a positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency on the continued availability of Iclusig(R)(ponatinib) in the EU for use in patients with leukaemias in its authorized indications with extra safety precautions to safeguard patients against an increased risk of occlusive vascular events.
Looking to deliver value for its stockholders in both the near and long term, Crown Equity Holdings Inc.(CRWE) is refocusing its strategic plan to improve the potential future growth for the company, targeting the multi-billion dollar online b2b market, with its ts iB2B Global project.
The price of Cubist Pharmaceuticals Inc.(CBST) stock jumped $5.26 (or +8.03%) to $70.76 after the company reported positive top-line results from pivotal Phase 3 clinical trial of its antibiotic candidate ceftolozane/tazobactam in complicated urinary tract infections.
CBST's ceftolozane/tazobactam, an antibiotic candidate being developed to treat certain Gram-negative infections, met its primary endpoint of statistical non-inferiority compared to levofloxacin (10% non-inferiority margin)
Full article at http://drstockpick.com/26645/stock-alerts/cub...